DHA

Quick Summary

DHA (docosahexaenoic acid, C22:6 n-3) is the long-chain marine omega-3 that is physically built into the structure of the brain and retina. It is one of three members of the omega-3 family (with EPA and plant-based ALA); this page treats DHA on its own. For the family overview and the EPA-vs-DHA-vs-ALA framework, see the omega-3 hub; for the inflammation, cardiovascular, and mood side, see the EPA sub-page.

• What DHA is. A 22-carbon, 6-double-bond omega-3 fatty acid — the most unsaturated fatty acid commonly found in human tissue. It is the major structural fatty acid of neural and retinal membranes: roughly 40% of the polyunsaturated fatty acids in brain phospholipids and around 50% in the outer-segment membranes of retinal rod photoreceptors. Where EPA is best understood as a signaling and metabolic fatty acid, DHA is best understood as a structural one.
• Where it comes from. DHA's sources are oily fish and fish oil and, equally first-line, algae oil — microalgae are the original organisms that synthesize DHA, and fish acquire it by eating algae. Algae oil is a genuine primary DHA source (it is the source of the DHA in infant formula worldwide), not a niche alternative. Cod liver oil also supplies DHA. Plant-based ALA (flaxseed, chia, walnut) converts to DHA at below 5% whole-body in most adults.

What the human-evidence record actually shows:

• Pregnancy and infant development — DHA's strongest domain. The Cochrane systematic review of omega-3 in pregnancy (PMID 30480773; 70 trials, 19,927 participants) reported a reduction of approximately 42% in early preterm birth before 34 weeks. DHA is structurally essential for fetal and infant brain and retinal development, and the WHO/ISSFAL endorse at least 200 mg/day DHA during pregnancy and lactation.
• Cognition is nuanced — and honestly negative for established disease. There is meta-analytic support for modest memory benefit in older adults with mild memory complaints (PMID 25786262) and a protective dose-response signal for omega-3/n-3 PUFA — an omega-3-blend effect, not DHA-specific — in adults without dementia (PMID 38468309). But supplementation does not reverse established Alzheimer's disease (PMID 38924283; PMID 28986068), and a dedicated DHA systematic review found minimal or no pooled effect on memory, attention, working memory, or executive function in age-related decline (PMID 32060571).
• Eye and retina — structural support, but no AMD prevention. DHA is structurally essential for fetal/infant retinal development and the EFSA authorizes a "maintenance of normal vision" claim at 250 mg/day. But omega-3 does not prevent or slow age-related macular degeneration (Cochrane PMID 25856365 + AREDS2).
• Cardiovascular — DHA is part of the blend story, not a standalone REDUCE-IT. DHA contributes to the triglyceride-lowering effect of an EPA+DHA blend (PMID 37264945), but the landmark positive trial (REDUCE-IT, PMID 30415628) used pure EPA, and the blend trials VITAL (PMID 30415637) and STRENGTH (PMID 33190147) were null. DHA-only cardiovascular outcome evidence is weaker than pure-EPA evidence.

Critical distinction — DHA is not EPA. DHA's evidence concentrates on brain and retinal structure (fetal/infant development, vision, cognitive maintenance); EPA's concentrates on inflammation, cardiovascular, and mood. They are not interchangeable — most notably, DHA-predominant formulations do not show a clear antidepressant effect, while EPA-predominant ones do (PMID 31383846; PMID 26978738). See the EPA sub-page for the signaling side.

Bottom line: DHA is genuinely and uniquely important for what it builds — the developing fetal and infant brain and retina, and the structural maintenance of neural and visual tissue across the lifespan. Its developmental evidence is its strongest. Its cognition-in-disease and AMD nulls are an essential part of the honest picture, and its cardiovascular evidence is best read through the EPA+DHA blend rather than as a standalone effect.

What is DHA? Chemistry, sources, and the DHA-vs-EPA split

DHA is a 22-carbon, 6-double-bond marine omega-3 and the major structural fatty acid of brain grey matter and retinal photoreceptors; its sources are oily fish and — equally first-line — algae oil, the original organism that synthesizes DHA.

DHA (docosahexaenoic acid) is a long-chain polyunsaturated fatty acid with twenty-two carbons and six double bonds, the first of which sits at the third carbon from the methyl end of the chain — the structural feature that makes it an "omega-3." It is the longest and most unsaturated of the nutritionally important omega-3 fatty acids, and that high degree of unsaturation gives the membranes it occupies their characteristic fluidity. It is a member of the omega-3 family alongside EPA (the shorter, signaling-and-metabolic fatty acid) and ALA (the short-chain plant precursor). Where EPA is best understood as a signaling fatty acid and ALA as a precursor, DHA is best understood as a structural one.

DHA at a glance

Where DHA comes from — fish and algae, both first-line

A useful correction for DHA specifically is that algae oil is not a fallback. For DHA, algae are the source — fish are simply a step further along the same food chain. The practical hierarchy of DHA sources is:

• Fatty fish and fish oil — a primary dietary source. Salmon, mackerel, sardine, herring, and anchovy are the richest everyday fish sources, and fish oil is the form used in much of the randomized-trial evidence. Natural fish oil is DHA-and-EPA together; concentrated products vary in their EPA:DHA ratio.
• Algae oil — an equally first-line DHA source. Marine microalgae (Schizochytrium sp., Crypthecodinium cohnii) are the organisms that originally synthesize DHA in the marine food chain — fish acquire DHA by eating algae. Most algae oils are DHA-dominant, which makes them a natural fit when DHA is the priority, and algae-sourced DHA is the standard DHA in infant formula worldwide. Algae oil is vegetarian, vegan, kosher, and halal compatible; it is produced by closed-system fermentation (no marine contaminants); and it is fish-allergy safe. For DHA, algae oil stands on equal footing with fish oil — a meaningful contrast with EPA, where algae oil is more often a secondary choice and an EPA-enriched strain is required.
• Cod liver oil — a DHA source with a caveat. Cod liver oil supplies DHA (and EPA) along with high levels of vitamins A and D. It is a legitimate DHA source, but pregnant people and others should avoid stacking cod liver oil with separate vitamin A supplementation; a refined fish oil or an algae oil is preferable for DHA-only support.
• Plant-source ALA — an inefficient indirect route. Flaxseed, chia, and walnut provide ALA, which the body converts onward to DHA at below 5% whole-body in most adults — even lower than the conversion to EPA. ALA is essential and worthwhile, but it is not a dependable way to reach a meaningful DHA intake, and it is the wrong tool for DHA-dependent outcomes such as fetal neural development. See the flaxseed (ALA) sub-page.

The correction worth remembering: for DHA, algae oil is a primary source, not a fallback — it is where the DHA in infant formula comes from, and it is the dependable first-line vegan route to direct DHA.

DHA vs EPA — different molecules, different jobs

The single most useful framing for DHA is the contrast with its sister fatty acid EPA. They co-occur in fish and are often sold together, but their evidence records diverge sharply.

This divergence is not cosmetic. A product's EPA:DHA ratio determines which evidence base it draws on. A high-DHA algae softgel marketed for pregnancy or cognition is the right tool for fetal neural development and structural support, but it is not a substitute for an EPA-predominant product used for mood or inflammation, and vice versa.

Mechanism of Action

DHA works principally as a structural fatty acid — it is the dominant polyunsaturated component of neuronal and retinal photoreceptor membranes — and secondarily as a substrate for D-series resolvins, a modulator of neurotransmitter and BDNF signaling, and a contributor to the triglyceride-lowering effect of an EPA+DHA blend.

DHA exerts its effects through several converging molecular mechanisms, but its defining role is structural — it is the omega-3 that tissue is physically built from.

1 · Structural membrane phospholipid incorporation — the defining DHA role. DHA is incorporated into the phospholipids of cell membranes, where its six double bonds give the membrane high fluidity and flexibility. It is concentrated to a remarkable degree in the central nervous system (≈40% of brain phospholipid PUFA, especially in synaptic membranes) and in the retina (≈50% of the PUFA in rod photoreceptor outer-segment membranes). This structural prominence is why adequate DHA is non-negotiable during periods of rapid neural and retinal growth — pregnancy, infancy, and early childhood — and is supportive of maintenance across the lifespan. DHA's structural residence in neural and retinal tissue is the single most important fact about it.

2 · Maternal-to-fetal transfer and developmental accretion. DHA is preferentially transferred across the placenta, and the largest fetal accretion occurs in the third trimester and continues through the first months of life via breast milk — a window in which the infant's own synthesis is insufficient to meet demand. This is the biological basis for the EFSA maternal-DHA claim and for the WHO/ISSFAL pregnancy and lactation recommendations.

3 · Specialized pro-resolving mediators (D-series). DHA is the precursor for a family of lipid signaling molecules — the D-series resolvins (RvD1 through RvD6), protectin D1, and maresin 1 — that, like EPA's E-series resolvins, actively terminate inflammation and promote return to tissue homeostasis. Protectin D1 (also called neuroprotectin D1 in neural tissue) is of particular interest in the retina and brain.

4 · Neurotransmitter and BDNF modulation. DHA upregulates brain-derived neurotrophic factor (BDNF) and influences membrane-dependent neurotransmitter signaling and neuronal membrane receptor function. These pathways provide the neurobiological context for DHA's role in neural development and structural cognitive maintenance — though, as the evidence sections below make clear, this mechanistic plausibility does not translate into cognitive restoration in established Alzheimer's disease.

5 · Contribution to triglyceride reduction within a blend. Like EPA, DHA activates PPAR-α and contributes to reduced hepatic VLDL secretion and accelerated clearance of circulating triglycerides. In practice this effect is most relevant as part of an EPA+DHA blend, which lowers serum triglycerides by 15–30% at 2–4 g/day; there is no DHA-only cardiovascular outcome trial comparable to the pure-EPA REDUCE-IT.

DHA's mechanistic case — especially its structural role — is supported by tissue-composition data (brain and retinal phospholipid analysis), maternal-fetal transfer studies, the red-blood-cell membrane Omega-3 Index, and animal developmental models. The mechanistic evidence for DHA's structural and developmental role is strong; the honest caveat is that structural plausibility in the adult brain does not, by itself, predict a treatment effect in established neurodegenerative disease.

Evidence-Based Benefits

The DHA evidence record is strongest where the biology is most clearly structural — maternal and infant development — and is honestly negative or null in several places where DHA is popularly assumed to help, most notably established Alzheimer's disease and age-related macular degeneration. This page presents both, in the transparency tradition of NIH-ODS, Cochrane, and Examine.com. Each sub-section indicates the evidence character, the strongest individual studies, and the relevant limitations.

Dosage by Context

For maintenance of normal brain function and vision the EFSA recognizes a 250 mg/day DHA threshold; pregnancy and lactation call for at least 200 mg/day DHA in addition to the general omega-3 intake; the FDA guidance is ≤2 g/day EPA+DHA from supplements (total intake up to 3 g/day considered safe), with atrial-fibrillation risk rising at 4 g/day.

The right DHA dose depends on the outcome — and, because DHA's strongest evidence is developmental, the most important dosing context is pregnancy and lactation. The table below summarizes the dose ranges supported by the strongest evidence cited above.

Key dose caveats.

• Direct DHA beats ALA conversion for DHA-dependent outcomes. Whole-body ALA-to-DHA conversion is below 5% in most adults, so for pregnancy, infancy, and reliable DHA status, a direct source (fish oil or algae oil) is the dependable route rather than relying on flaxseed.
• Algae oil is the first-line vegan DHA source. It is where the DHA in infant formula comes from, and it lets a plant-based diet reach an adequate DHA intake without a marine animal source — a contrast with EPA, where algae oil is more often secondary.
• The EFSA recognizes a 250 mg/day DHA threshold for the "maintenance of normal brain function" and "maintenance of normal vision" claims, and a 200 mg/day DHA maternal threshold (in addition to the general 250 mg/day EPA+DHA intake) for the fetal/infant brain-development claim.
• At 4 g/day, atrial-fibrillation risk is increased for high-dose omega-3 generally (REDUCE-IT and STRENGTH both reported it). High-dose omega-3 should be used under physician supervision, particularly in people with a history of atrial fibrillation or other heart-rhythm disorders.
• EPA:DHA ratio is not cosmetic. Match the ratio to your reason for taking it: DHA-predominant for structural/brain and pregnancy support; EPA-predominant for mood and inflammation (see the EPA sub-page).

Safety, Side Effects, and Drug Interactions

Common, mild side effects include a fishy-taste reflux or belching (especially with lower-purity fish-oil products on an empty stomach) and gastrointestinal discomfort (nausea, loose stools, bloating). Most side effects are dose- and form-dependent; higher-quality forms taken with a fat-containing meal substantially reduce reflux. Algae-DHA products tend to have a low odor.

Excellent safety profile within recommended ranges. DHA has an excellent safety profile within recommended supplementation ranges. Very-high-dose DHA (above 5 g/day) is not advised without clinician oversight.

Atrial fibrillation at high dose. As detailed in the Cardiovascular and Negative Findings sections above, 4 g/day doses of omega-3 generally have been associated with an approximately 1% absolute increase in atrial-fibrillation incidence in the STRENGTH trial (mixed EPA+DHA), with a smaller signal in the pure-EPA REDUCE-IT trial. People with a history of atrial fibrillation, atrial flutter, or other heart-rhythm disorders should use high-dose omega-3 only under medical supervision.

Bleeding risk. Omega-3, including DHA, inhibits platelet aggregation in laboratory and short-term human studies. Reviews have concluded that clinically important bleeding has not been demonstrated in randomized trials at supplemental doses, including in patients on anticoagulants and antiplatelet agents. The theoretical concern remains, and patients taking anticoagulants in combination with high-dose omega-3 should inform their physician and have routine monitoring.

Pregnancy and breastfeeding. DHA supplementation at 200–300 mg/day during pregnancy and lactation is recommended by the World Health Organization and the International Society for the Study of Fatty Acids and Lipids, and randomized-trial safety data are extensive (including the 70-trial Cochrane review). During pregnancy, prefer products tested for low mercury, polychlorinated biphenyls (PCBs), and dioxins, or use algae oil, which is produced in closed-system fermentation and is free of marine contaminants.

Infants and toddlers. DHA is required for normal neural and retinal development, and endogenous synthesis is insufficient. The DHA in standardized infant formula is sourced from algae and is well established.

Allergy. People with fish or shellfish allergy should avoid fish-derived and krill-derived oils and use algae-sourced DHA instead — which is produced by closed-system fermentation and has no protein cross-reactivity with fish or shellfish allergens. For DHA, this is a particularly clean option because algae oil is a first-line DHA source.

Cod liver oil — a specific case. Cod liver oil contains high levels of vitamins A and D in addition to DHA and EPA. Pregnant people and others should avoid stacking cod liver oil with separate vitamin A supplementation; for general DHA support, a refined fish oil or algae oil is preferable.

Drug interactions.

• Anticoagulants and antiplatelet agents: see "Bleeding risk" above — clinically important bleeding has not been demonstrated, but monitoring is reasonable.
• Antihypertensives: mild additive blood-pressure lowering is possible at higher omega-3 doses.
• Statins: combination is safe.

Sources — Fish and Algae Oil (Both First-Line for DHA)

DHA is obtained from marine sources and — equally first-line — from marine microalgae. The hierarchy below reflects the DHA-specific reality that algae oil is a primary source, not a fallback: algae are the original organisms that synthesize DHA, and algae-sourced DHA is the standard DHA in infant formula worldwide.

Source bottom line. For DHA, algae oil and fish oil are both first-line: algae oil is the original organism that synthesizes DHA and the standard source of DHA in infant formula, while fish oil offers the highest concentration and the deepest clinical evidence base. Krill oil offers phospholipid-bound DHA at lower concentration. ALA from flaxseed and other plants is an inefficient indirect route, not a substitute — particularly for DHA, where conversion is even lower than for EPA. For quality criteria (third-party purity certification, DHA-milligram disclosure, freshness/TOTOX, form transparency), see the omega-3 hub, which covers these in detail for the whole family.

Tags

Body Systems: Neurological & Cognitive · Vision · Reproductive

Mechanisms: Cell membrane phospholipid integration · Specialized pro-resolving mediators (SPMs) biosynthesis · Neurotransmitter modulation · PPAR-α activation

Evidence Tier: Meta-analysis supported

Dosage Range: 200 mg/d DHA above the general 250 mg/d EPA+DHA RDA (EFSA maternal claim · pregnancy/lactation) · 250 mg/d DHA (EFSA normal brain function and vision maintenance) · ≤2 g/d EPA+DHA from supplements per FDA (total intake up to 3 g/d considered safe) · ≤5 g/d EFSA tolerable upper

Last Evidence Review: 2026-06-04 · Reviewed by Evidence Synthesis Lead + Regulatory Compliance Lead

Related Goals

• cognitive-support
• eye-protection
• reproductive-health

Related Lifestyles

• pregnancy
• plant-based
• senior-60-plus

Related Ingredients

• omega-3
• epa
• algae-oil
• fish-oil
• krill-oil
• ala

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

Pregnancy and Infant Development

1. PMID 30480773 · Middleton P et al. (2018) · "Omega-3 fatty acid addition during pregnancy" · Cochrane Database of Systematic Reviews · 70 RCTs n=19,927 · early preterm birth <34 weeks −42%

Brain and Cognition (including disease nulls)

2. PMID 25786262 · Yurko-Mauro K et al. (2015) · DHA / DHA+EPA memory-function meta-analysis in older adults with mild memory complaints · PLOS ONE
3. PMID 38468309 · 2024 dose-response meta-analysis · omega-3 PUFA cognitive outcomes in adults without dementia · BMC Medicine
4. PMID 32060571 · Balachandar R et al. (2020) · DHA supplementation systematic review and meta-analysis · 10 RCTs n≈2,327 older adults · minimal/no pooled effect on memory, attention, working memory, executive function · European Journal of Clinical Pharmacology
5. PMID 38924283 · Calderon Martinez et al. (2024) · meta-analysis of RCTs in diagnosed Alzheimer's disease · no cognitive improvement
6. PMID 28986068 · Araya-Quintanilla et al. (2020) · meta-analysis of RCTs in diagnosed Alzheimer's disease · no disease reversal

Eye Health (AMD Null)

7. PMID 25856365 · Lawrenson JG, Evans JR (2015) · "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration" · Cochrane Database of Systematic Reviews · no benefit on AMD progression (reinforced by AREDS2)

Cardiovascular (EPA+DHA blend context)

8. PMID 30415628 · Bhatt DL et al. (2019) · "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia" (REDUCE-IT) · NEJM · 4 g/day pure EPA (no DHA) · primary CV composite HR 0.75 (−25%) — EPA-specific, not DHA
9. PMID 30415637 · Manson JE et al. (2019) · (VITAL) · NEJM · n=25,871 · 1 g/day EPA+DHA blend · primary CV null (HR 0.92)
10. PMID 33190147 · Nicholls SJ et al. (2020) · (STRENGTH) · JAMA · n=13,078 · 4 g/day EPA+DHA carboxylic acid · primary null + atrial fibrillation HR ~1.69
11. PMID 37264945 · Triglyceride dose-response meta-analysis · 2–4 g/day EPA+DHA → 15–30% serum triglyceride reduction (DHA contributes within the blend)

EPA-vs-DHA Distinction (Mood)

12. PMID 31383846 · Liao Y et al. (2019) · meta-analysis of 26 RCTs n=2,160 · EPA-predominant antidepressant effect · DHA-predominant null · Translational Psychiatry
13. PMID 26978738 · Mocking RJT et al. (2016) · meta-analysis + meta-regression of 13 RCTs n=1,233 · higher EPA dose predicts better outcomes (the mood-relevant form is EPA, not DHA) · Translational Psychiatry

Regulatory and Public-Health References (not counted in PMID total)

• EFSA Reg 432/2012 · "DHA contributes to the maintenance of normal brain function" and "DHA contributes to the maintenance of normal vision" — at a daily intake of 250 mg DHA · "Maternal intake of DHA contributes to normal brain development of the foetus and breastfed infants" — at ≥200 mg DHA/day in addition to the recommended 250 mg DHA+EPA · ≤5 g/day EPA+DHA tolerable upper intake (EFSA 2012)
• FDA · supplement labels should not recommend exceeding 2 g/day EPA+DHA; total intake up to 3 g/day considered GRAS · GRAS status for fish oil and algae DHA oil
• ANVISA (Brazil) · IN 28/2018 Anexo V · authorized functional claim "Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos" — for supplements providing at least 1,500 mg EPA+DHA per day
• China NHC / SAMR · DHA and EPA recognized as n-3 PUFA nutrient sources; fish oil and DHA algae oil listed on the health-food raw-material directory (filing-based)
• WHO / ISSFAL · ≥200 mg/day DHA during pregnancy and lactation
• AHA 2017 Scientific Statement · omega-3 bleeding risk · no clinically important bleeding demonstrated at supplemental doses

For the full omega-3 family evidence base — including EPA-specific cardiovascular and mood data, forms comparison (rTG/EE/TG/PL), and quality criteria — see the omega-3 cluster hub.

Related Pages

• Omega-3 (overview) — EPA, DHA, and ALA in one place; the full marine + plant evidence base, forms comparison, and quality criteria.
• EPA — the signaling omega-3 monomer; inflammation, triglycerides, conditional cardiovascular, and mood. DHA's complement, not its substitute.
• Algae oil — the original organism that synthesizes DHA; the first-line vegan DHA source and the source of DHA in infant formula.
• Fish oil — a primary dietary source of DHA (with EPA) and the largest clinical evidence base.
• Flaxseed (ALA) — the plant precursor; why ALA does not reliably substitute for direct DHA (conversion is even lower than for EPA).

Educational Disclaimer

This page is educational reference content and is not medical advice. Discuss supplement use with a qualified healthcare provider, particularly if you are pregnant, breastfeeding, take prescription medications, or have a history of atrial fibrillation, bleeding disorders, or other medical conditions.

Frequently Asked Questions

The questions below are the most-searched questions on DHA across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.